MedVector introduces its Prime-Controltm Technology to provide contract research organizations and pharmaceutical sponsors with access to subjects for new clinical trials.
FREMONT, CA: MedVector has begun a nationwide rollout of its Prime-Controltm Technology, which will provide contract research organizations (CROs) and pharmaceutical sponsors with access to numerous patients without the requirement of new clinical trial sites.
MedVector is the only organization that collaborates with CROs, sponsors, and patient recruitment firms to increase subject participation beyond the current clinical trial sites.